Advanced Clear Cell Renal Cell Carcinoma After PD-1/PD-L1 Therapy
MRKMerck & CoCatalyst overview
Research summary
This catalyst tracks a PDUFA approval decision for WELIREG/Belzutifan (MK-6482) + LENVIMA/Lenvatinib (E7080) (HIF-2α Combo) in Advanced Clear Cell Renal Cell Carcinoma After PD-1/PD-L1 Therapy. The expected timing is based on the latest available company guidance and may change.
02/28/26:- LITESPARK-011 Ph3 interim PFS positive; FDA accepted sNDAs; PDUFA October 4, 2026.
Verification
Confirm timing and program details against the company announcement or filing.